Literature DB >> 7128675

Kinetics of phenobarbital in normal subjects and epileptic patients.

A J Wilensky, P N Friel, R H Levy, C P Comfort, S P Kaluzny.   

Abstract

The kinetics of phenobarbital (PB) were evaluated in six normal subjects and six epileptic patients treated with phenytoin or carbamazepine. Each normal subject received three single doses of PB: PB-sodium 130 mg i.v. (IV), PB sodium 10 mg i.m. (IM), and PB acid 100 mg orally (PO), in random order at least one month apart. After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg. Absolute bioavailability of IM PB was 101 +/- 11%. Peak serum PB concentrations were achieved from 2 to 8 h after IM administration, and from 0.5 to 4 h after PO administration. Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg. Phenobarbital appears to represent an exception among antiepileptic drugs, in that pharmacokinetic data obtained in normal car reasonably be extrapolated to the epileptic population.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7128675     DOI: 10.1007/bf01061382

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Plasma levels and urinary excretion of three barbituric acids after oral administration to man.

Authors:  P LOUS
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1954

2.  Plasma and cerebrospinal fluid concentrations of phenobarbital in infants given single doses.

Authors:  B Jalling
Journal:  Dev Med Child Neurol       Date:  1974-12       Impact factor: 5.449

3.  Disappearance of phenobarbital and diphenylhydantoin from serum of children.

Authors:  L K Garrettson; P G Dayton
Journal:  Clin Pharmacol Ther       Date:  1970 Sep-Oct       Impact factor: 6.875

4.  The clinical significance of microsomal enzyme induction in the therapy of epileptic patients.

Authors:  E Sotaniemi; P Arvela; H Hakkarainen; E Huhti
Journal:  Ann Clin Res       Date:  1970-09

5.  Bioavailability of oral and intramuscular phenobarbital.

Authors:  C T Viswanathan; H E Booker; P G Welling
Journal:  J Clin Pharmacol       Date:  1978 Feb-Mar       Impact factor: 3.126

6.  The effect of liver disease in man on the disposition of phenobarbital.

Authors:  J Alvin; T McHorse; A Hoyumpa; M T Bush; S Schenker
Journal:  J Pharmacol Exp Ther       Date:  1975-01       Impact factor: 4.030

7.  Factors influencing plasma phenobarbitone levels in epileptic patients.

Authors:  M J Eadie; C M Lander; W D Hooper; J H Tyrer
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

8.  Plasma concentrations of phenobarbital in the treatment of seizures in newborns.

Authors:  B Jalling
Journal:  Acta Paediatr Scand       Date:  1975-05

9.  Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: a kinetic approach.

Authors:  P R Martin; C M Bhushan; B M Kapur; E A Whiteside; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

10.  Phenobarbital--valporic acid interaction.

Authors:  I H Patel; R H Levy; R E Cutler
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

View more
  14 in total

1.  The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance.

Authors:  T Pullar; S Kumar; H Chrystyn; P Rice; S Peaker; M Feely
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 2.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning.

Authors:  D Jacobsen; E Wiik-Larsen; T Dahl; E Enger; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Pharmacokinetics of phenobarbital in the cat following multiple oral administration.

Authors:  S M Cochrane; J M Parent; W D Black; D G Allen; J H Lumsden
Journal:  Can J Vet Res       Date:  1990-06       Impact factor: 1.310

Review 5.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 6.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

7.  Pharmacokinetics of phenobarbital in the cat following intravenous and oral administration.

Authors:  S M Cochrane; W D Black; J M Parent; D G Allen; J H Lumsden
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

Review 8.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

Review 9.  Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.

Authors:  Y Sawada; M Hanano; Y Sugiyama; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1985-10

10.  Functional Exploration of the Pulmonary NEB ME.

Authors:  Inge Brouns; Line Verckist; Isabel Pintelon; Jean-Pierre Timmermans; Dirk Adriaensen
Journal:  Adv Anat Embryol Cell Biol       Date:  2021       Impact factor: 1.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.